Abstract
Ovarian carcinoma, particularly of the serous type, has an almost universal predilection to involve the serosal cavities, matched only by malignant mesothelioma. The formation of peritoneal effusions, and not uncommonly pleural effusions, is a hallmark of this disease. The number of scientific studies focusing on the biology of ovarian carcinoma cells in effusions consequently surpasses that of any other malignancy. Carcinoma cells in effusions are considerably different from their counterparts in solid lesions, reflecting both tumor progression and growth in anchorage-independent manner. These cells are further characterized by chemoresistance and have cancer stem cell characteristics. In recent years, more focus has been directed to studies limited to one histotype, mainly high-grade serous carcinoma. This chapter discusses studies which have analyzed the expression, clinical relevance, and therapeutic potential of cancer-associated molecules in ovarian carcinoma effusions.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.
Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16:201–18.
Thibault B, Castells M, Delord JP, Couderc B. Ovarian cancer microenvironment: implications for cancer dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 2014;33:17–39.
Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research. Front Oncol. 2013;3:256.
Davidson B. Recently identified drug resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn. 2016;16:569–78.
Shirayoshi Y, Hatta K, Hosoda M, Tsunasawa S, Sakiyama F, Takeichi M. Cadherin cell adhesion molecules with distinct binding specificities share a common structure. EMBO J. 1986;5:2485–8.
Behrens J. Cadherins and catenins: role in signal transduction and tumor progression. Cancer Metastasis Rev. 1999;18:15–30.
Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell. 1991;66:107–19.
Hajra KM, Fearon ER. Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer. 2002;34:255–68.
Bruner HC, Derksen PWB. Loss of E-Cadherin-dependent cell-cell adhesion and the development and progression of cancer. Cold Spring Harb Perspect Biol. 2018;10(3):pii: a029330.
Kourtidis A, Lu R, Pence LJ, Anastasiadis PZ. A central role for cadherin signaling in cancer. Exp Cell Res. 2017;358:78–85.
Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 2009;119:1429–37.
Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415–28.
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420–8.
Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet. 1994;7:98–102.
Palacios J, Gamallo C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998;58:1344–7.
Davidson B, Tropé CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol. 2012;2:33.
Davidson B, Berner A, Nesland JM, Risberg B, Berner HS, Tropé CG, Kristensen GM, Bryne M, Flørenes VA. E-cadherin and α-, β- and γ-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol. 2000;192:460–9.
Sivertsen S, Berner A, Michael C, Bedrossian B, Davidson B. Ovarian carcinoma and malignant mesothelioma cells in effusions have comparable cadherin expression. Acta Cytol. 2006;50:603–7.
Elloul S, Bukholt Elstrand M, Nesland JM, Tropé CG, Kvalheim G, Goldberg I, Reich R, Davidson B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103:1631–43.
Davidson B, Holth A, Hellesylt E, Tan TZ, Huang RYJ, Tropé CG, Nesland JM, Thiery JP. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage serous ovarian carcinoma effusions. Hum Pathol. 2015;46:1–8.
Kim G, Davidson B, Henning R, Wang J, Yu M, Annunziata C, Hetland T, Kohn EC. Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer. 2012;118:1543–53.
Elloul S, Silins I, Tropé CG, Benshushan A, Davidson B, Site-dependent RR. expression of E-cadherin transcriptional regulators in ovarian carcinoma. Virchows Arch. 2006;449:520–8.
Elloul S, Vaksman O, Tuft Stavnes H, Tropé CG, Davidson B, Reich R. Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions. Clin Exp Metastasis. 2010;27:161–72.
Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91–100.
Sanders RJ, Mainiero F, Giancotti FP. The role of integrins in tumorigenesis and metastasis. Cancer Invest. 1998;16:329–44.
Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25:234–40.
Moser TL, Pizzo SV, Bafetti LM, Fishman DA, Stack MS. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the α2β1 integrin. Int J Cancer. 1996;67:695–701.
Strobel T, Cannistra SA. β1-integrins partly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. Gynecol Oncol. 1999;73:362–7.
Lessan K, Aguiar DJ, Oegema T, Siebenson L, Skubitz AP. CD44 and β1 integrin mediate ovarian carcinoma cell adhesion to peritoneal mesothelial cells. Am J Pathol. 1999;154:1525–37.
Skubitz APN, Bast RC Jr, Wayner EA, Letourneau PC, Wilke MS. Expression of α6 and β4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol. 1996;148:1445–61.
Cannistra SA, Ottensmeier C, Niloff J, Orta B, DiCarlo J. Expression and function of β1 and αvβ3 integrins in ovarian cancer. Gynecol Oncol. 1995;58:216–25.
Davidson B, Goldberg I, Reich R, Tell L, Dong HP, Tropé CG, Risberg B, Kopolovic J. αv and β1 integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol. 2003;90:248–57.
Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, Berner A, Nesland JM, Kopolovic J. αV integrin is a novel marker of poor prognosis in advanced-stage ovarian carcinoma. Clin Cancer Res. 2001;7:4073–9.
Byers LJ, Osborne JL, Carson LF, Carter JR, Haney AF, Weinberg JB, Ramakrishnan S. Increased levels of laminin in ascitic fluid of patients with ovarian cancer. Cancer Lett. 1995;88:67–72.
Givant-Horwitz V, Davidson B, van de Putte G, Dong HP, Goldberg I, Amir S, Kristensen GB, Reich R. Expression of the 67kDa laminin receptor and the α6 integrin subunit in serous ovarian carcinoma. Clin Exp Metastasis. 2003;20:599–609.
Ahmed N, Riley C, Oliva K, Rice G, Quinn M. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer. 2005;92:1475–85.
Bar JK, Grelewski P, Popiela A, Noga L, Rabczyñski J. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol. 2004;95:23–31.
Cracchiolo BM, Hanauske-Abel HM, Schwartz PE, Chambers JT, Holland B, Chambers SK. Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Independent prognosticators for progression-free interval and survival. Gynecol Oncol. 2002;87:24–33.
Zhu GG, Risteli J, Puistola U, Kauppila A, Risteli L. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity. Cancer Res. 1993;53:5028–32.
Kohn EC, Travers LA, Kassis J, Broome U, Klominek J. Malignant effusions are sources of fibronectin and other promigratory and proinvasive components. Diagn Cytopathol. 2005;33:300–8.
Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer. 1992;70:2137–42.
Menzin AW, Loret de Mola JR, Bilker WB, Wheeler JE, Rubin SC, Feinberg RF. Identification of oncofetal fibronectin in patients with advanced epithelial ovarian cancer: detection in ascitic fluid and localization to primary sites and metastatic implants. Cancer. 1998;82:152–8.
Tabariès S, Siegel PM. The role of claudins in cancer metastasis. Oncogene. 2017;36:1176–90.
Tassi RA, Bignotti E, Falchetti M, Ravanini M, Calza S, Ravaggi A, Bandiera E, Facchetti F, Pecorelli S, Santin AD. Claudin-7 expression in human epithelial ovarian cancer. Int J Gynecol Cancer. 2008;18:1262–71.
Lonardi S, Manera C, Marucci R, Santoro A, Lorenzi L, Facchetti F. Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions. Diagn Cytopathol. 2011;39:313–7.
Jo VY, Cibas ES, Pinkus GS. Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol. 2014;122:299–306.
Davidson B, Zhang Z, Kleinberg L, Li M, Flørenes VA, Wang TL, IeM S. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res. 2006;12:5944–50.
Kleinberg L, Holth A, Fridman E, Schwartz I, Shih IM, Davidson B. The diagnostic role of claudins in serous effusions. Am J Clin Pathol. 2007;127:928–37.
Kleinberg L, Holth A, Tropé CG, Reich R, Davidson B. Claudin upregulation in ovarian carcinoma effusions is associated with poor survival. Hum Pathol. 2008;39:747–57.
Underhill C. CD44: the hyaluronan receptor. J Cell Sci. 1992;103:293–8.
Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 2010;46:1271–7.
Senbanjo LT, Chellaiah MA. CD44: a multifunctional cell surface adhesion receptor is a regulator of progression and metastasis of cancer cells. Front Cell Dev Biol. 2017;5:18.
Muinao T, Deka Boruah HP, Pal M. Diagnostic and prognostic biomarkers in ovarian cancer and the potential roles of cancer stem cells—an updated review. Exp Cell Res. 2018;362(1):1–10.
Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res. 1993;53:3830–8.
Meunier L, Puiffe ML, Le Page C, Filali-Mouhim A, Chevrette M, Tonin PN, Provencher DM, Mes-Masson AM. Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Transl Oncol. 2010;3:230–8.
Yang W, Toffa SE, Lohn JW, Seifalian AM, Winslet MC. Malignant ascites increases the antioxidant ability of human ovarian (SKOV-3) and gastric adenocarcinoma (KATO-III) cells. Gynecol Oncol. 2005;96:430–8.
Berner HS, Davidson B, Berner A, Risberg B, Nesland JM. Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions. Virchows Arch. 2000;436:330–5.
Berner HS, Davidson B, Berner A, Risberg B, Kristensen GB, Tropé CG, Van de Putte G, Nesland JM. Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma—diagnostic and prognostic implications. Clin Exp Metastasis. 2000;18:197–202.
Dong WG, Sun XM, Yu BP, Luo HS, Yu JP. Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World J Gastroenterol. 2003;9:2596–600.
Taylor DD, Gercel-Taylor C, Gall SA. Expression and shedding of CD44 variant isoforms in patients with gynecologic malignancies. J Soc Gynecol Investig. 1996;3:289–94.
Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77–99.
Carraway KL 3rd, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol. 2007;78:1–22.
van Putten JPM, Strijbis K. Transmembrane mucins: signaling receptors at the intersection of inflammation and cancer. J Innate Immun. 2017;9:281–99.
Singh AP, Chaturvedi P, Batra SK. Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy. Cancer Res. 2007;67:433–6.
Gautam SK, Kumar S, Cannon A, Hall B, Bhatia R, Nasser MW, Mahapatra S, Batra SK, Jain M. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. Expert Opin Ther Targets. 2017;21:657–69.
Davidson B, Baekelandt M, Shih IM. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol. 2007;35:756–60.
Iacono KT, Brown AL, Greene MI, Saouaf SJ. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol. 2007;83:283–95.
Xin X, Zeng X, Gu H, Li M, Tan H, Jin Z, Hua T, Shi R, Wang H. CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis. Sci Rep. 2016;6:32804.
Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis. 2003;20:161–9.
Davidson B, Givant-Horwitz V, Lazarovici P, Risberg B, Nesland JM, Tropé CG, Schaefer E, Reich R. Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis. 2003;20:621–31.
Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, Risberg B, Kopolovic J, Kristensen GB, Tropé CG, van de Putte G, Reich R. Caveolin-1 expression in ovarian carcinoma is MDR1 independent. Am J Clin Pathol. 2002;117:225–34.
Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272–80.
Teng KK, Hempstead BL. Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Mol Life Sci. 2004;61:35–48.
Nakagawara A. Trk receptor tyrosine kinases: A bridge between cancer and neural development. Cancer Lett. 2001;169:107–14.
Fanburg-Smith JC, Miettinen M. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneuronal tumors: a study of 1,150 tumors and fetal and adult normal tissues. Hum Pathol. 2001;32:976–83.
Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5:25–34.
Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR, Meric-Bernstam F, Hong DS. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58–66.
Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R. Expression levels of the NGF receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res. 2001;7:3457–64.
Davidson B, Reich R, Lazarovici P, Nesland JM, Risberg B, Tropé CG, Flørenes VA. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res. 2003;9:2248–59.
Yu X, Liu L, Cai B, He Y, Wan X. Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci. 2008;99:543–52.
Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.
Bjorklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta. 2005;1755:37–69.
Levin M, Udi Y, Solomonov I, Sagi I. Next generation matrix metalloproteinase inhibitors—novel strategies bring new prospects. Biochim Biophys Acta. 2017;1864:1927–39.
Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochim Biophys Acta. 2017;1864:2043–55.
Young TN, Rodriguez GC, Rinehart AR, Bast RCJ, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol. 1996;62:89–99.
Fishman DA, Bafetti LM, Banionis S, Kearns AS, Chilukuri K, Stack MS. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer. 1997;80:1457–63.
Fishman DA, Bafetti LM, Stack MS. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Invasion Metastasis. 1996;16:150–9.
Sun XM, Dong WG, Yu BP, Luo HS, Yu JP. Detection of type IV collagenase activity in malignant ascites. World J Gastroenterol. 2003;9:2592–5.
Davidson B, Reich R, Berner A, Givant-Horwitz V, Goldberg I, Risberg B, Kristensen GB, Tropé CG, Bryne M, Kopolovic J, Nesland JM. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer. 2001;37:2040–9.
Davidson B, Goldberg I, Berner A, Nesland JM, Givant-Horwitz V, Bryne M, Risberg B, Kristensen GB, Tropé CG, Kopolovic J, Reich R. Expression of membrane-type 1,2 and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions. Am J Clin Pathol. 2001;115:517–24.
Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualized management of patients with cancer. Clin Biochem. 2004;37:541–8.
Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932–42.
Su SC, Lin CW, Yang WE, Fan WL, Yang SF. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets. 2016;20:551–66.
Young TN, Rodriguez GC, Moser TL, Bast RC Jr, Pizzo SV, Stack MS. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol. 1994;170:1285–96.
Sier CF, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 1998;58:1843–9.
Sier CF, Nicoletti I, Santovito ML, Frandsen T, Aletti G, Ferrari A, Lissoni A, Giavazzi R, Blasi F, Sidenius N. Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thromb Haemost. 2004;91:403–11.
Chambers SK, Gertz RE Jr, Ivins CM, Kacinski BM. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer. 1995;75:1627–33.
Price FV, Chambers SK, Chambers JT, Carcangiu ML, Schwartz PE, Kohorn EI, Stanley ER, Kacinski BM. Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival. Am J Obstet Gynecol. 1993;168:520–7.
Kobayashi H, Hirashima Y, Sun GW, Ohi H, Fujie M, Terao T. Identification and characterization of a Kunitz-type protease inhibitor in ascites fluid from patients with ovarian carcinoma. Int J Cancer. 2000;87:44–54.
Avgeris M, Scorilas A. Kallikrein-related peptidases (KLKs) as emerging therapeutic targets: focus on prostate cancer and skin pathologies. Expert Opin Ther Targets. 2016;20:801–18.
Shih IM, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Müller-Holzner E, Gastl G, Zhang Z, Diamandis EP. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol. 2007;105:501–7.
Davidson B, Xi Z, Klokk TI, Tropé CG, Dørum A, Scheistrøen M, Saatcioglu F. Kallikrein 4 expression is upregulated in ovarian carcinoma cells in effusions. Am J Clin Pathol. 2005;123:360–8.
Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, Parsons PG, Clements JA. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res. 2010;70:2624–33.
Trackman PC. Lysyl oxidase isoforms and potential therapeutic opportunities for fibrosis and cancer. Expert Opin Ther Targets. 2016;20:935–45.
Sebban S, Davidson B, Reich R. Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities. Virchows Arch. 2009;454:71–9.
Sebban S, Golan-Gerstl R, Karni R, Vaksman O, Davidson B, Reich R. Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. Clin Exp Metastasis. 2013;30:103–17.
Kassis J, Klominek J, Kohn EC. Tumor microenvironment: what can effusions teach us? Diagn Cytopathol. 2005;33:316–9.
Li H, Batth IS, Qu X, Xu L, Song N, Wang R, Liu Y. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer. 2017;16:6.
Bach LA, Headey SJ, Norton RS. IGF-binding proteins—the pieces are falling into place. Trends Endocrinol Metab. 2005;16:228–34.
Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23:824–54.
Slipicevic A, Øy GF, Askildt IC, Holth A, Hellesylt E, Flørenes VA, Davidson B. The diagnostic and prognostic role of the insulin growth factor pathway members IGF-II and IGFBP3 in serous effusions. Hum Pathol. 2009;40:527–37.
Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185–8.
Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442–7.
Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 2006;580:2879–87.
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.
Presta M, Chiodelli P, Giacomini A, Rusnati M, Ronca R. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171–87.
Clayton NS, Wilson AS, Laurent EP, Grose RP, Carter EP. Fibroblast growth factor-mediated crosstalk in cancer etiology and treatment. Dev Dyn. 2017;246:493–501.
Alfaro C, Sanmamed MF, Rodríguez-Ruiz ME, Teijeira Á, Oñate C, González Á, Ponz M, Schalper KA, Pérez-Gracia JL, Melero I. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat Rev. 2017;60:24–31.
Olson TA, Mohanraj D, Carson LF, Ramakrishnan S. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 1994;54:276–80.
Boocock CA, Charnock-Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR, Smith SK. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995;87:506–16.
Barton DP, Cai A, Wendt K, Young M, Gamero A, De Cesare S. Angiogenic protein expression in advanced epithelial ovarian cancer. Clin Cancer Res. 1997;3:1579–86.
Santin AD, Hermonat PL, Ravaggi A, Cannon MJ, Pecorelli S, Parham GP. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol. 1999;20:177–81.
Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marmé D, Gastl G. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999;85:178–87.
Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene. 2001;20:5878–87.
Davidson B, Reich R, Kopolovic J, Berner A, Nesland JM, Kristensen GB, Tropé CG, Bryne M, Risberg B, van de Putte G, Goldberg I. Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis. 2002;19:135–44.
Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta. 2001;1471:M99–M108.
Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J. 2017;284:42–55.
Davidson B, Shafat I, Ilan N, Tropé CG, Vlodavsky I, Reich R. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol. 2007;104:311–9.
Ong CHP, Bateman A. Progranulin (Granulin-epithelin precursor, PC-cell derived growth factor, Acrogranin) in proliferation and tumorigenesis. Histol Histopathol. 2003;18:1275–88.
Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn EC. Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer. Oncogene. 2005;24:7084–93.
Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Tropé CG, Kohn EC. Granulin-epithelin precursor (GEP) is a novel prognostic marker in epithelial ovarian cancer. Cancer. 2004;100:2139–47.
Meulmeester E, Ten Dijke P. The dynamic roles of TGF-β in cancer. J Pathol. 2011;223:205–18.
Smith AL, Robin TP, Ford HL. Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res. 2012;18:4514–21.
Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010;10:415–24.
Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577–84.
Saltzman AK, Hartenbach EM, Carter JR, Contreras DN, Twiggs LB, Carson LF, Ramakrishnan S. Transforming growth factor-alpha levels in the serum and ascites of patients with advanced epithelial ovarian cancer. Gynecol Obstet Invest. 1999;47:200–4.
Gutgold N, Davidson B, Catane LJ, Holth A, Hellesylt E, Tropé CG, Dørum A, Reich R. TGFβ splicing and canonical pathway activation in high-grade serous carcinoma. Virchows Arch. 2017;470:665–78.
Bock AJ, Stavnes HT, Kempf T, Tropè CG, Berner A, Davidson B, Staff AC. Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions. Int J Gynecol Cancer. 2010;20:1448–55.
Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14:1931–7.
ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis. 2008;11:79–89.
Ollauri-Ibáñez C, López-Novoa JM, Pericacho M. Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies. Expert Opin Biol Ther. 2017;17:1053–63.
Bock AJ, Tuft Stavnes H, Kærn J, Berner A, Staff AC, Davidson B. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status. Tumour Biol. 2011;32:589–96.
Matei D, Emerson RE, Lai YC, Baldridge LA, Rao J, Yiannoutsos C, Donner DD. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. Oncogene. 2006;25:2060–9.
Richardson M, Gunawan J, Hatton MW, Seidlitz E, Hirte HW, Singh G. Malignant ascites fluid (MAF), including ovarian-cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis. Gynecol Oncol. 2002;86:279–87.
Kleinberg L, Pradhan M, Tropé CG, Nesland JM, Davidson D, Risberg B. Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors. Diagn Cytopathol. 2008;36:637–44.
Deshpande A, Sicinski P, Hinds PW. Cyclins and cdks in development and cancer: a perspective. Oncogene. 2005;24:2909–15.
Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol. 1995;147:545–60.
Graña X, Reddy EP. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995;11:211–9.
Watson JE, Gabra H, Taylor KJ, Rabiasz GJ, Morrison H, Perry P, Smyth JF, Porteous DJ. Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. Genome Res. 1999;9:226–33.
Goto T, Takano M, Hirata J, Kohno T, Ohtsuka S, Fujiwara K, Tsuda H. p16INK4a expression in cytology of ascites and response to chemotherapy in advanced ovarian cancer. Int J Cancer. 2009;125:339–44.
Davidson B, Risberg B, Berner A, Nesland JM, Tropé CG, Kristensen GB, Bryne M, van de Putte G, Flørenes VA. Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions—biological and prognostic implications. Gynecol Oncol. 2001;83:249–56.
Davidson B, Skrede M, Silins I, Shih IM, Tropé CG, Flørenes VA. Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer. 2007;110:1264–71.
Salani R, Davidson B, Fiegl M, Marth C, Müller-Holzner E, Gastl G, Huang HY, Hsiao JC, Lin HS, Wang TL, Lin BL, Shih IM. Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions. Clin Cancer Res. 2007;13:5805–9.
Provencher DM, Lounis H, Fink D, Drouin P, Mes-Masson AM. Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer. Tumour Biol. 1997;18:167–74.
Kappes S, Milde-Langosch K, Kressin P, Passlack B, Dockhorn-Dworniczak B, Röhlke P, Löning T. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry. Int J Cancer. 1995;64:52–9.
Angelopoulou K, Diamandis EP. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur J Cancer. 1997;33:115–21.
Abendstein B, Marth C, Müller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer. 2000;88:1432–7.
Montenarh M, Harloziñska A, Bar JK, Kartarius S, Günther J, Sedlaczek P. p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer. Int J Oncol. 1998;13:605–10.
Ashkenazi A. Targeting death and decoy receptors of the tumor-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420–30.
Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45–65.
Twomey JD, Kim SR, Zhao L, Bozza WP, Zhang B. Spatial dynamics of TRAIL death receptors in cancer cells. Drug Resist Updat. 2015;19:13–21.
Reichmann E. The biological role of the Fas/FasL system during tumor formation and progression. Semin Cancer Biol. 2002;12:309–15.
Siegmund D, Lang I, Wajant H. Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2. FEBS J. 2017;284:1131–59.
Lane D, Goncharenko-Khaider N, Rancourt C, Piché A. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene. 2010;29:3519–31.
Lane D, Matte I, Rancourt C, Piché A. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer. J Ovarian Res. 2010;3:1.
Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol. 2008;111:330–5.
Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res. 2003;63:5573–81.
Ciaravino G, Bhat M, Manbeian CA, Teng NN. Differential expression of CD40 and CD95 in ovarian carcinoma. Eur J Gynaecol Oncol. 2004;25:27–32.
Dong HP, Kleinberg L, Silins I, Flørenes VA, Tropé CG, Risberg B, Nesland JM, Davidson B. Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma. Cancer. 2008;112:84–93.
Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277–88.
Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9:231–41.
Dong HP, Kleinberg L, Davidson B, Risberg B. Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry. Nat Protoc. 2008;3:955–64.
Kleinberg L, Dong HP, Holth A, Risberg B, Tropé CG, Nesland JM, Flørenes VA, Davidson B. Cleaved caspases and NF-κB are prognostic factors in metastatic ovarian carcinoma. Hum Pathol. 2009;40:795–806.
Dong HP, Holth A, Kleinberg L, Ruud MG, Elstrand MB, Tropé CG, Davidson B, Risberg B. Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the Annexin-V/7-AAD assay - Clinical relevance and comparison to other apoptosis parameters. Am J Clin Pathol. 2009;132:756–62.
Dong HP, Ree Rosnes AK, Bock AJ, Holth A, Flørenes VA, Tropé CG, Risberg B, Davidson B. Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions. Cytopathology. 2011;22:373–82.
Fulda S. Molecular pathways: targeting inhibitor of apoptosis proteins in cancer—from molecular mechanism to therapeutic application. Clin Cancer Res. 2014;20:289–95.
Peery RC, Liu JY, Zhang JT. Targeting survivin for therapeutic discovery: past, present, and future promises. Drug Discov Today. 2017;22:1466–77.
Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE. Immunohistochemical detection of XIAP in body cavity effusions and washes. Mod Pathol. 2005;18:1618–22.
Kleinberg L, Flørenes VA, Silins I, Haug K, Tropé CG, Nesland JM, Davidson B. Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma. Cancer. 2007;109:228–38.
Danial NN. Bcl-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res. 2007;13:7254–63.
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16:273–84.
Liu JR, Fletcher B, Page C, Hu C, Nunez G, Baker V. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Gynecol Oncol. 1998;70:398–403.
Bunkholt Elstrand M, Kleinberg L, Kohn EC, Tropé CG, Davidson B. Expression and clinical role of anti-apoptotic proteins of the Bag, heat shock and Bcl-2 families in effusions, primary tumors and solid metastases in ovarian carcinoma. Int J Gynecol Pathol. 2009;28:211–21.
Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive and treatment implications. Cell Stress Chaperones. 2005;10:86–103.
Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle. 2006;5:2592–601.
Beere HM. “The stress of dying”: the role of heat shock proteins in the regulation of apoptosis. J Cell Sci. 2004;117:2641–51.
Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat shock proteins and cancer. Trends Pharmacol Sci. 2017;38:226–56.
Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18:345–60.
Elstrand MB, Stavnes HT, Tropé CG, Davidson B. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions. Hum Pathol. 2012;43:529–35.
Behl C. Breaking BAG: the Co-Chaperone BAG3 in health and disease. Trends Pharmacol Sci. 2016;37:672–88.
Ma HT, Poon RY. How protein kinases co-ordinate mitosis in animal cells. Biochem J. 2011;435:17–31.
Damodaran AP, Vaufrey L, Gavard O, Prigent C. Aurora A Kinase is a priority pharmaceutical target for the treatment of cancers. Trends Pharmacol Sci. 2017;38:687–700.
Marumoto T, Zhang D, Saya H. Aurora-A—a guardian of poles. Nat Rev Cancer. 2005;5:42–50.
Vader G, Lens SM. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta. 2008;1786:60–72.
Hetland TE, Nymoen DA, Holth A, Brusegard K, Flørenes VA, Kærn J, Tropé CG, Davidson B. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance. Hum Pathol. 2013;44:777–85.
Davidson B, Nymoen DA, Elgaaen BV, Staff AC, Tropé CG, Kærn J, Reich R, Falkenthal TE. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma. Virchows Arch. 2014;464:701–7.
Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016;37:872–81.
Slipicevic A, Holth A, Hellesylt E, Tropé CG, Davidson B, Flørenes VA. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol Oncol. 2014;135:118–24.
Pakish JB, Jazaeri AA. Immunotherapy in gynecologic cancers: are we there yet? Curr Treat Options Oncol. 2017;18:59.
Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;24:3–11.
Ventriglia J, Paciolla I, Pisano C, Cecere SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G, Setola SV, Arenare L, Pignata S, Della Pepa C. Immunotherapy in ovarian, endometrial and cervical cancer: state of the art and future perspectives. Cancer Treat Rev. 2017;59:109–16.
Fumita Y, Tanaka F, Saji F, Nakamuro K. Immunosuppressive factors in ascites fluids from ovarian cancer patients. Am J Reprod Immunol. 1984;6:175–8.
Akyol S, Gercel-Taylor C, Reynolds LC, Taylor DD. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling. Gynecol Oncol. 2006;101:481–6.
Taylor DD, Gerçel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005;92:305–11.
Gordon IO, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res. 2006;12:1515–24.
Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res. 1996;2:161–73.
Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol. 1999;163:6251–60.
Takaishi K, Komohara Y, Tashiro H, Ohtake H, Nakagawa T, Katabuchi H, Takeya M. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. Cancer Sci. 2010;101:2128–36.
Webb TJ, Giuntoli RL 2nd, Rogers O, Schneck J, Oelke M. Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. Clin Cancer Res. 2008;14:7652–8.
Wischhusen J, Waschbisch A, Wiendl H. Immune-refractory cancers and their little helpers—an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E. Semin Cancer Biol. 2007;17:459–68.
Morandi F, Rizzo R, Fainardi E, Rouas-Freiss N, Pistoia V. Recent advances in our understanding of HLA-G biology: lessons from a wide spectrum of human diseases. J Immunol Res. 2016;2016:4326495.
Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E, Grosse-Wilde H, Cheng CC, Kurman RJ, Shih IM. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res. 2003;9:4460–4.
Davidson B, Bukholt Elstrand M, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope’ CG, Shih IM. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol. 2005;96:42–7.
Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest. 1993;91:2194–206.
Stadlmann S, Amberger A, Pollheimer J, Gastl G, Offner FA, Margreiter R, Zeimet AG. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol. 2005;97:784–9.
Hurteau JA, Simon HU, Kurman C, Rubin L, Mills GB. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. Am J Obstet Gynecol. 1994;170:918–28.
Barton DP, Blanchard DK, Michelini-Norris B, Nicosia SV, Cavanagh D, Djeu JY. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer. Blood. 1993;81:424–9.
Garg R, Wollan M, Galic V, Garcia R, Goff BA, Gray HJ, Swisher E. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol. 2006;103:793–6.
Schröder W, Ruppert C, Bender HG. Concomitant measurements of interleukin-6 (IL-6) in serum and peritoneal fluid of patients with benign and malignant ovarian tumors. Eur J Obstet Gynecol Reprod Biol. 1994;56:43–6.
Moradi MM, Carson LF, Weinberg B, Haney AF, Twiggs LB, Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer. 1993;72:2433–40.
Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer. 1994;73:1882–8.
Ripley D, Shoup B, Majewski A, Chegini N. Differential expression of interleukins IL-13 and IL-15 in normal ovarian tissue and ovarian carcinomas. Gynecol Oncol. 2004;92:761–8.
Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Müller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol. 1998;16:1861–8.
Mustea A, Pirvulescu C, Könsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer. Cytokine. 2008;42:77–84.
Matte I, Lane D, Laplante C, Rancourt C, Piché A. Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res. 2012;2:566–80.
Kolomeyevskaya N, Eng KH, Khan AN, Grzankowski KS, Singel KL, Moysich K, Segal BH. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer. Gynecol Oncol. 2015;138:352–7.
Naldini A, Morena E, Belotti D, Carraro F, Allavena P, Giavazzi R. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thromb Haemost. 2011;106:705–11.
Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med. 2010;16:133–44.
Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72.
Scotton CJ, Wilson JL, Milliken D, Stamp G, Balkwill FR. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res. 2001;61:4961–5.
Scotton CJ, Wilson JL, Scott K, Stamp G, Wilbanks GD, Fricker S, Bridger G, Balkwill FR. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002;62:5930–8.
Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res. 2002;8:1108–14.
Dong HP, Bunkholt Elstrand M, Holth A, Silins I, Berner A, Tropé CG, Davidson B, Risberg B. NK and B cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol. 2006;125:451–8.
Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem. 2002;277:24584–93.
Bamias A, Tsiatas ML, Kafantari E, Liakou C, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Tsitsilonis O, Bamia C, Papatheodoridis G, Politi E, Archimandritis A, Antsaklis A, Dimopoulos MA. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol. 2007;106:75–81.
Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A, Antsaklis A, Dimopoulos MA. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol. 2008;108:421–7.
Melichar B, Nash MA, Lenzi R, Platsoucas CD, Freedman RS. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol. 2000;119:19–27.
Landskron J, Helland Ø, Torgersen KM, Aandahl EM, Gjertsen BT, Bjørge L, Taskén K. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol Immunother. 2015;64:337–47.
Reijnhart RM, Bieber MM, Teng NN. FACS analysis of peritoneal lymphocytes in ovarian cancer and control patients. Immunobiology. 1994;191:1–8.
Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–6.
Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006;66:605–12.
Risberg B, Davidson B, Nielsen S, Dong HP, Christensen J, Johansen P, Asschenfeldt P, Berner A. Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry. Diagn Cytopathol. 2001;25:214–9.
Wang R, Zhang T, Ma Z, Wang Y, Cheng Z, Xu H, Li W, Wang X. The interaction of coagulation factor XII and monocyte/macrophages mediating peritoneal metastasis of epithelial ovarian cancer. Gynecol Oncol. 2010;117:460–6.
Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schwörer AM, Wagner U, Müller-Brüsselbach S, Müller R. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer. 2014;134:32–42.
Adhikary T, Wortmann A, Finkernagel F, Lieber S, Nist A, Stiewe T, Wagner U, Müller-Brüsselbach S, Reinartz S, Müller R. Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients. BMC Genomics. 2017;18:243.
Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537–49.
Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 2010;1802:396–405.
Rauch N, Rukhlenko OS, Kolch W, Kholodenko BN. MAPK kinase signalling dynamics regulate cell fate decisions and drug resistance. Curr Opin Struct Biol. 2016;41:151–8.
Givant-Horwitz V, Davidson B, Lazarovici P, Schaefer E, Nesland JM, Tropé CG, Reich R. Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol. 2003;91:160–72.
Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Tropé CG, Reich R. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol. 2004;93:517–23.
Davidson B, Espina V, Flørenes VA, Liotta LA, Kristensen GB, Trope’ CG, Berner A, Kohn EC. Proteomic profiling of malignant ovarian cancer effusions: survival and injury pathways discriminate clinical outcome. Clin Cancer Res. 2006;12:791–9.
Dokianakis DN, Varras MN, Papaefthimiou M, Apostolopoulou J, Simiakaki H, Diakomanolis E, Spandidos DA. Ras gene activation in malignant cells of human ovarian carcinoma peritoneal fluids. Clin Exp Metastasis. 1999;17:293–7.
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–35.
Manning BD, Toker A. AKT/PKB signaling: navigating the network. Cell. 2017;169:381–405.
Davidson B, Hadar R, Schlossberg A, Sternlicht T, Slipicevic A, Skrede M, Risberg B, Flørenes VA, Kopolovic J, Reich R. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol. 2008;39:87–95.
Cao J, Lou S, Ying M, Yang B. DJ-1 as a human oncogene and potential therapeutic target. Biochem Pharmacol. 2015;93:241–50.
Bunkholt Elstrand M, Dong HP, Ødegaard E, Holth A, Elloul S, Reich R, Tropé CG, Davidson B. Mammalian target of rapamycin is a biomarker of poor survival in metastatic ovarian carcinoma. Hum Pathol. 2010;41:794–804.
Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006;13:759–72.
Neumann M, Naumann M. Beyond IkappaBs: alternative regulation of NF-kappaB activity. FASEB J. 2007;21:2642–54.
Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8:49–62.
Seth A, Watson DK. Ets transcription factors and their emerging roles in human cancer. Eur J Cancer. 2005;41:2462–78.
Verger A, Duterque-Coquillaud M. When Ets transcription factors meet their partners. Bioessays. 2002;24:362–70.
Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol. 2001;2:827–37.
Sizemore GM, Pitarresi JR, Balakrishnan S, Ostrowski MC. The ETS family of oncogenic transcription factors in solid tumours. Nat Rev Cancer. 2017;17:337–51.
Davidson B, Risberg B, Goldberg I, Nesland JM, Berner A, Trope´ CG, Kristensen GB, Bryne M, Reich R. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol. 2001;25:1493–500.
Davidson B, Goldberg I, Reich R, Tell L, Baekelandt M, Kristensen GB, Berner A, Kopolovic J. The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions. Clin Exp Metastasis. 2004;21:191–9.
Brenne K, Nymoen DA, Hetland TE, Trope' CG, Davidson B. Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival. Hum Pathol. 2012;43:496–505.
Sertznig P, Seifert M, Tilgen W, Reichrath J. Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol. 2007;212:1–12.
Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004;4:61–70.
Davidson B, Hadar R, Tuft Stavnes H, Trope' CG, Reich R. Expression of the peroxisome proliferator-activated receptors (PPAR)-α, -β and -γ in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. Hum Pathol. 2009;40:705–13.
Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma. Gynecol Oncol. 2006;103:831–40.
Denkert C, Köbel M, Pest S, Koch I, Berger S, Schwabe M, Siegert A, Reles A, Klosterhalfen B, Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol. 2002;160:893–903.
Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S. Malignant effusions contain lysophosphatidic acid (LPA)-like activity. Ann Oncol. 1998;9:437–42.
Xiao YJ, Schwartz B, Washington M, Kennedy A, Webster K, Belinson J, Xu Y. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem. 2001;290:302–13.
Lee MJ, Jeon ES, Lee JS, Cho M, Suh DS, Chang CL, Kim JH. Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells. J Cell Biochem. 2008;104:499–510.
Harel-Dassa K, Yedgar S, Tropé CG, Davidson B, Reich R. Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma. Hum Pathol. 2017;62:115–21.
Melnikova VO, Bar-Eli M. Transcriptional control of the melanoma malignant phenotype. Cancer Biol Ther. 2008;7:997–1003.
Pellikainen JM, Kosma VM. Activator protein-2 in carcinogenesis with a special reference to breast cancer—a mini review. Int J Cancer. 2007;120:2061–7.
Ødegaard E, Staff AC, Kærn J, Flørenes VA, Kopolovic J, Tropé CG, Abeler VM, Reich R, Davidson B. AP-2γ is a marker of tumor progression in ovarian carcinoma. Gynecol Oncol. 2006;100:462–8.
St Pierre R, Kadoch C. Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities. Curr Opin Genet Dev. 2017;42:56–67.
Shih IM, Sheu JJ, Santillan A, Nakayama K, Yen MJ, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B, Wang TL. Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A. 2005;102:14004–9.
Davidson B, Trope’ CG, Wang TL, Shih IM. Expression of the chromatin remodeling factor Rsf-1 in effusions is a novel predictor of poor survival in ovarian carcinoma. Gynecol Oncol. 2006;103:814–9.
Collins T, Stone JR, Williams AJ. All in the family: the BTB/POZ, KRAB, and SCAN domains. Mol Cell Biol. 2001;21:3609–15.
Stogios PJ, Downs GS, Jauhal JJ, Nandra SK, Prive GG. Sequence and structural analysis of BTB domain proteins. Genome Biol. 2005;6:R82.
Cha XY, Pierce RC, Kalivas PW, Mackler SA. NAC-1, a rat brain mRNA, is increased in the nucleus accumbens three weeks after chronic cocaine self-administration. J Neurosci. 1997;17:6864–71.
Nakayma K, Nakayma N, Davidson B, Sheu J, Jinawath N, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, Shih IM. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A. 2006;103:18739–44.
Davidson B, Berner A, Tropé CG, Wang TL, IeM S. Expression and clinical role of the BTB/POZ protein NAC-1 in ovarian carcinoma effusions. Hum Pathol. 2007;38:1030–6.
Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih IM. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol. 2010;2010:285191.
D’Souza B, Meloty-Kapella L, Weinmaster G. Canonical and non-canonical Notch ligands. Curr Top Dev Biol. 2010;92:73–129.
Artavanis-Tsakonas S, Muskavitch MA. Notch: the past, the present, and the future. Curr Top Dev Biol. 2010;92:1–29.
Koch U, Radtke F. Notch signaling in solid tumors. Curr Top Dev Biol. 2010;92:411–55.
Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011;8:97–106.
Nowell CS, Radtke F. Notch as a tumour suppressor. Nat Rev Cancer. 2017;17:145–59.
Park JT, Li M, Nakayama K, Mao TL, Davidson B, Zhang Z, Kurman RJ, Eberhart CG, Shih IM, Wang TL. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006;66:6312–8.
Choi JH, Park JT, Davidson B, Morin PJ, Shih IM, Wang TL. Jagged-1 and notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res. 2008;68:5716–23.
Park J, Chen X, Tropè CG, Davidson B, Shih IM, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol. 2010;177:1087–94.
Burleson KM, Casey RC, Skubitz KM, Pambuccian SE, Oegema TR Jr, Skubitz AP. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol. 2004;93:170–81.
Burleson KM, Boente MP, Pambuccian SE, Skubitz AP. Disaggregation and invasion of ovarian carcinoma ascites spheroids. J Transl Med. 2006;4:6.
Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009;8:158–66.
Runz S, Keller S, Rupp C, Stoeck A, Issa Y, Koensgen D, Mustea A, Sehouli J, Kristiansen G, Altevogt P. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol. 2007;107:563–71.
Davidson B. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. Hum Pathol. 2016;58:123–7.
Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, Shevde L, Rocconi RP. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis. 2012;29:939–48.
Meng E, Mitra A, Tripathi K, Finan MA, Scalici J, McClellan S, Madeira da Silva L, Reed E, Shevde LA, Palle K, Rocconi RP. ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling. PLoS One. 2014;9:e107142.
Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS One. 2012;7:e46858.
Abubaker K, Luwor RB, Zhu H, McNally O, Quinn MA, Burns CJ, Thompson EW, Findlay JK, Ahmed N. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden. BMC Cancer. 2014;14:317.
Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB, Brown R. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 2011;10:325–35.
Neradil J, Veselska R. Nestin as a marker of cancer stem cells. Cancer Sci. 2015;106:803–11.
Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311–20.
Hetland TE, Hellesylt E, Flørenes VA, Tropé C, Davidson B, Kærn J. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance. Hum Pathol. 2011;42:1019–26.
Salazar MD, Ratnam M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev. 2007;26:141–52.
Kelemen LE. The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer. 2006;119:243–50.
Cheung A, Bax HJ, Josephs DH, Ilieva KM, Pellizzari G, Opzoomer J, Bloomfield J, Fittall M, Grigoriadis A, Figini M, Canevari S, Spicer JF, Tutt AN, Karagiannis SN. Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016;7:52553–74.
Mantovani LT, Miotti S, Ménard S, Canevari S, Raspagliesi F, Bottini C, Bottero F, Colnaghi MI. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19. Eur J Cancer. 1994;30A:363–9.
Corona G, Toffoli G, Fabris M, Viel A, Zarrelli A, Donada C, Boiocchi M. Homocysteine accumulation in human ovarian carcinoma ascitic/cystic fluids possibly caused by metabolic alteration of the methionine cycle in ovarian carcinoma cells. Eur J Cancer. 1997;33:1284–90.
Forster MD, Ormerod MG, Agarwal R, Kaye SB, Jackman AL. Flow cytometric method for determining folate receptor expression on ovarian carcinoma cells. Cytometry A. 2007;71:945–50.
Yuan Y, Nymoen DA, Dong HP, Bjørang O, Shih IM, Low PS, Trope' CG, Davidson B. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol. 2009;40:1453–60.
Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22:7280–95.
Parker AL, Teo WS, McCarroll JA, Kavallaris M. An emerging role for tubulin isotypes in modulating cancer biology and chemotherapy resistance. Int J Mol Sci. 2017;18. pii: E1434.
Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Band Horwitz S. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest. 1997;100:1282–93.
Chu TM, Lin TH, Kawinski E. Detection of soluble P-glycoprotein in culture media and extracellular fluids. Biochem Biophys Res Commun. 1994;203:506–12.
Kerr EH, Frederick PJ, Egger ME, Stockard CR, Sellers J, DellaManna D, Oelschlager DK, Amm HM, Eltoum IE, Straughn JM, Buchsbaum DJ, Grizzle WE, McNally LR. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. Ann Surg Oncol. 2013;20:3059–65.
Huang H, Li Y, Liu J, Zheng M, Feng Y, Hu K, Huang Y, Huang Q. Screening and identification of biomarkers in ascites related to intrinsic chemoresistance of serous epithelial ovarian cancers. PLoS One. 2012;7:e51256.
Kase H, Kodama S, Nagai E, Tanaka K. Glutathione S-transferase pi immunostaining of cisplatin-resistant ovarian cancer cells in ascites. Acta Cytol. 1998;42:1397–402.
Brown JS, O’Carrigan B, Jackson SP, Yap TA. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017;7:20–37.
Ibanez de Caceres I, Battagli C, Esteller M, Herman JG, Dulaimi E, Edelson MI, Bergman C, Ehya H, Eisenberg BL, Cairns P. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 2004;64:6476–81.
Ercoli A, Ferrandina G, Raspaglio G, Marone M, Maggiano N, Del Mastro P, Benedetti Panici P, Mancuso S, Scambia G. hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer. Br J Cancer. 1999;80:1665–71.
Stevens EV, Raffeld M, Espina V, Kristensen GB, Tropé CG, Kohn EC, Davidson B. Expression of Xeroderma Pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer. 2005;103:2313–9.
Counter CM, Hirte HW, Bacchetti S, Harley CB. Telomerase activity in human ovarian carcinoma. Proc Natl Acad Sci U S A. 1994;91:2900–4.
Tseng CJ, Jain S, Hou HC, Liu W, Pao CC, Lin CT, Horng SG, Soong YK, Hsueh S. Applications of the telomerase assay in peritoneal washing fluids. Gynecol Oncol. 2001;81:420–3.
Murakami J, Nagai N, Ohama K. Telomerase activity in body cavity fluid and peritoneal washings in uterine and ovarian cancer. J Int Med Res. 1998;26:129–39.
Elg SA, Mayer AR, Carson LF, Twiggs LB, Hill RB, Ramakrishnan S. Alpha-1 acid glycoprotein is an immunosuppressive factor found in ascites from ovaria carcinoma. Cancer. 1997;80:1448–56.
Elg SA, Carson LF, Fowler JM, Twiggs LB, Moradi MM, Ramakrishnan S. Ascites levels of haptoglobin in patients with ovarian cancer. Cancer. 1993;71:3938–41.
Gericke B, Raila J, Sehouli J, Haebel S, Könsgen D, Mustea A, Schweigert FJ. Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer. 2005;5:133.
Schweigert FJ, Raila J, Sehouli J, Buscher U. Accumulation of selected carotenoids, alpha-tocopherol and retinol in human ovarian carcinoma ascitic fluid. Ann Nutr Metab. 2004;48:241–5.
Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002;62:5358–64.
Hofmann M, Ruschenburg I. mRNA detection of tumor-rejection genes BAGE, GAGE, and MAGE in peritoneal fluid from patients with ovarian carcinoma as a potential diagnostic tool. Cancer. 2002;96:187–93.
Jeschke U, Mylonas I, Kunert-Keil C, Stahn R, Scholz C, Janni W, Kuhn C, Schröder E, Mayr D, Friese K. Immunohistochemistry, glycosylation and immunosuppression of glycodelin in human ovarian cancer. Histochem Cell Biol. 2009;131:283–95.
Kajiyama H, Kikkawa F, Maeda O, Suzuki T, Ino K, Mizutani S. Increased expression of dipeptidyl peptidase IV in human mesothelial cells by malignant ascites from ovarian carcinoma patients. Oncology. 2002;63:158–65.
Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res. 1999;5:3488–99.
Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, Kim NW. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006;66:1570–5.
Thomsen LL, Sargent JM, Williamson CJ, Elgie AW. Nitric oxide synthase activity in fresh cells from ovarian tumour tissue: relationship of enzyme activity with clinical parameters of patients with ovarian cancer. Biochem Pharmacol. 1998;56:1365–70.
Jandu N, Richardson M, Singh G, Hirte H, Hatton MW. Human ovarian cancer ascites fluid contains a mixture of incompletely degraded soluble products of fibrin that collectively possess an antiangiogenic property. Int J Gynecol Cancer. 2006;16:1536–44.
Wilhelm S, Schmitt M, Parkinson J, Kuhn W, Graeff H, Wilhelm OG. Thrombomodulin, a receptor for the serine protease thrombin, is decreased in primary tumors and metastases but increased in ascitic fluids of patients with advanced ovarian cancer FIGO IIIc. Int J Oncol. 1998;13:645–51.
Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, Morin PJ. Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res. 2000;60:6281–7.
Chen YC, Pohl G, Wang TL, Morin PJ, Risberg B, Kristensen GB, Yu A, Davidson B, Shih IM. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res. 2005;65:331–7.
Chen YC, Davidson B, Cheng CC, Maitra A, Giuntoli RL II, Hruban RH, Wang TL, Shih IM. Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. Biochim Biophys Acta. 2005;1730:96–102.
Nakayama K, Nakayama N, Davidson B, Katabuci H, Kurman RJ, Velculescu VE, Shih IM, Wang TL. Homozygous deletion of MKK4 in ovarian serous carcinomas. Cancer Biol Ther. 2006;5:630–4.
Rayhman O, Klipper E, Muller L, Davidson B, Reich R, Meidan R. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res. 2008;68:9265–73.
Mælandsmo GM, Flørenes VA, Nguyen MTP, Flatmark K, Davidson B. Different expression and clinical role of S100A4 in ovarian carcinoma at different anatomic sites. Tumor Biol. 2009;30:15–25.
Davidson B, Holth A, Moripen L, Trope' CG, Shih IM. Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol. 2011;42:991–7.
Reich R, Hadar S, Davidson B. Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma. Int J Mol Sci. 2011;12:1133–45.
Becker MA, Haluska P Jr, Bale LK, Oxvig C, Conover CA. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts. Mol Cancer Ther. 2015;14:973–81.
Bock AJ, Dong HP, Tropé CG, Staff AC, Risberg B, Davidson B. Nucleoside transporters are widely expressed in ovarian carcinoma effusions. Cancer Chemother Pharmacol. 2012;69:467–75.
Vaksman O, Davidson B, Tropé C, Reich R. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol. 2013;44:2677–83.
Hetland TE, Nymoen DA, Emilsen E, Kærn J, Tropé CG, Flørenes VA, Davidson B. MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival. Gynecol Oncol. 2012;126:460–5.
Hetland TE, Holth A, Kærn J, Flørenes VA, Tropé CG, Davidson B. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases. Virchows Arch. 2012;460:505–13.
Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. Hum Pathol. 2016;48:95–101.
Horwitz V, Davidson B, Stern D, Tropé CG, Tavor Re'em T, Reich R. Ezrin is associated with disease progression in ovarian carcinoma. PLoS One. 2016;11:e0162502.
Ioakim-Liossi A, Gagos S, Athanassiades P, Athanassiadou P, Gogas J, Davaris P, Markopoulos C. Changes of chromosomes 1, 3, 6, and 11 in metastatic effusions arising from breast and ovarian cancer. Cancer Genet Cytogenet. 1999;110:34–40.
Chang HW, Ali SZ, Cho SK, Kurman RJ, Shih IM. Detection of allelic imbalance in ascitic supernatant by digital single nucleotide polymorphism analysis. Clin Cancer Res. 2002;8:2580–5.
Lounis H, Mes-Masson AM, Dion F, Bradley WE, Seymour RJ, Provencher D, Tonin PN. Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene. 1998;17:2359–65.
Nagel H, Schulten HJ, Gunawan B, Brinck U, Füzesi L. The potential value of comparative genomic hybridization analysis in effusion-and fine needle aspiration cytology. Mod Pathol. 2002;15:818–25.
Brenne K, Nymoen DA, Reich R, Davidson B. PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma. Am J Clin Pathol. 2012;137:240–7.
Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma. Virchows Arch. 2012;460:193–202.
Davidson B, Stavnes HT, Hellesylt E, Hager T, Zeppa P, Pinamonti M, Wohlschlaeger J. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. Hum Pathol. 2016;47:104–8.
Yuan Y, Dong HP, Nymoen DA, Nesland JM, Wu C, Davidson B. PINCH-2 expression in cancers involving the serosal cavities using quantitative PCR. Cytopathology. 2011;22:22–9.
Yuan Y, Nymoen DA, Tuft Stavnes H, Rossnes AK, Bjørang O, Wu C, Nesland JM, Davidson B. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol. 2009;33:1673–82.
Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih IM, Wang TL. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med. 2011;15:535–44.
Bock AJ, Nymoen DA, Brenne K, Kærn J, Davidson B. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions. Hum Pathol. 2012;43:669–74.
Tuft Stavnes H, Nymoen DA, Hetland Falkenthal TE, Kærn J, Tropé CG, Davidson B. APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival. Am J Clin Pathol. 2014;142:51–7.
Stavnes HT, Holth A, Don T, Kærn J, Vaksman O, Reich R, Trope' CG, Davidson B. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Gynecol Oncol. 2013;129:358–63.
Stavnes HT, Nymoen DA, Langerød A, Holth A, Børresen Dale AL, Davidson B. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma. Virchows Arch. 2013;462:163–73.
Schaner ME, Davidson B, Skrede M, Reich R, Flørenes VA, Risberg B, Berner A, Goldberg I, Givant-Horwitz V, Tropé CG, Kristensen GB, Nesland JM, Børresen-Dale AL. Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. Mol Cancer. 2005;4:26.
Vaksman O, Stavnes HT, Kærn J, Trope CG, Davidson B, Reich R. miRNA profiling along tumor progression in ovarian carcinoma. J Cell Mol Med. 2011;15:1593–602.
Vaksman O, Hetland TE, Tropé CG, Reich R, Davidson B. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. Hum Pathol. 2012;43:2062–9.
Nymoen DA, Slipicevic A, Holth A, Emilsen E, Hetland Falkenthal TE, Tropé CG, Reich R, Flørenes VA, Davidson B. MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. Hum Pathol. 2016;54:74–81.
Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9:654–9.
Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531–48.
Moore C, Kosgodage U, Lange S, Inal JM. The emerging role of exosome and microvesicle- (EMV-) based cancer therapeutics and immunotherapy. Int J Cancer. 2017;141:428–36.
Vaksman O, Tropé C, Davidson B, Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis. 2014;35:2113–20.
Cappellesso R, Tinazzi A, Giurici T, Simonato F, Guzzardo V, Ventura L, Crescenzi M, Chiarelli S, Fassina A. Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014;122:685–93.
Broner EC, Tropé CG, Reich R, Davidson B. TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma. Hum Pathol. 2017;60:180–7.
Gillet JP, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, Ambudkar SV, Davidson B, Gottesman MM. Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions. Mol Pharm. 2011;8:2080–8.
Nymoen DA, Holth A, Hetland Falkenthal TE, Tropé CG, Davidson B. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma. Mol Cancer. 2015;14:44.
Gortzak-Uzan L, Ignatchenko A, Evangelou AI, Agochiya M, Brown KA, St Onge P, Kireeva I, Schmitt-Ulms G, Brown TJ, Murphy J, Rosen B, Shaw P, Jurisica I, Kislinger T. A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. J Proteome Res. 2008;7:339–51.
Gunawardana CG, Memari N, Diamandis EP. Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. Clin Biochem. 2009;42:426–9.
Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia. 2007;9:820–9.
Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap KL, Guo T, Lee CS, Wang W, Balgley BM, Davidson B, Wang TL, Shih IM. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One. 2010;5:e11198.
Saini U, Naidu S, Elnaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K. Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target. Oncogene. 2017;36:168–81.
Vettukattil R, Hetland TE, Flørenes VA, Kærn J, Davidson B, Bathen TF. Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma. Hum Pathol. 2013;44:1859–66.
Zennaro L, Vanzani P, Nicolè L, Cappellesso R, Fassina A. Metabonomics by proton nuclear magnetic resonance in human pleural effusions: a route to discriminate between benign and malignant pleural effusions and to target small molecules as potential cancer biomarkers. Cancer. 2017;125:341–8.
Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R. Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin Cancer Res. 2017;23:1263–73.
Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O’Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015;521(7553):489–94.
Shah RH, Scott SN, Brannon AR, Levine DA, Lin O, Berger MF. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma. Cancer Cytopathol. 2015;123:289–97.
Penner-Goeke S, Lichtensztejn Z, Neufeld M, Ali JL, Altman AD, Nachtigal MW, McManus KJ. The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples. PLoS Genet. 2017;13:e1006707.
Lund RJ, Huhtinen K, Salmi J, Rantala J, Nguyen EV, Moulder R, Goodlett DR, Lahesmaa R, Carpén O. DNA methylation and transcriptome changes associated with Cisplatin resistance in ovarian cancer. Sci Rep. 2017;7:1469.
Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, Webb JR, Watson PH, Nelson BH, Holt RA. Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol. 2013;229:515–24.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Davidson, B. (2018). Ovarian Cancer. In: Davidson, B., Firat, P., Michael, C. (eds) Serous Effusions. Springer, Cham. https://doi.org/10.1007/978-3-319-76478-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-319-76478-8_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-76477-1
Online ISBN: 978-3-319-76478-8
eBook Packages: MedicineMedicine (R0)